World's Best Scientists 2026 revealed!
John G. McHutchison

John G. McHutchison

D-Index & Metrics

Medicine

D-Index
142
Citations
101537
World Ranking
1535
National Ranking
892

Research.com Recognitions

  • 2018 - Fellow of the Australian Academy of Health and Medical Science
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

John G. McHutchison is affiliated with Duke University in the United States and has a research focus primarily in the field of Medicine. Their work encompasses several subfields including Epidemiology, Hepatology, Hematology, Genetics, and Molecular Biology.

The scientist's research spans main topics such as Hepatitis C virus research, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, HIV, Drug Use, Sexual Risk, Liver Disease and Transplantation, Influenza Virus Research Studies, and Blood groups and transfusion.

Recent published papers by John G. McHutchison include:

  • Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study, 2021, The Lancet. Gastroenterology & hepatology
  • Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure, 2021, Nature Communications
  • ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer, 2024, Hepatology
  • Quantitation of Pretreatment Serum IP-10 Improves the Predictive Value of an IL28B Gene Polymorphism for Hepatitis C Treatment Response, 2020, UNC Libraries
  • Reduced Hepatitis C Incidence Associated with Rapid Treatment Scale-Up in Australian Prisons: Treatment-as-Prevention in the SToP-C Study, 2020, SSRN Electronic Journal

Frequent co-authors collaborating with John G. McHutchison include:

  • Natasha K. Martin
  • Nezam H. Afdhal
  • Behzad Hajarizadeh
  • Jason Grebely
  • Marianne Byrne

The scientist often publishes work in venues such as UNC Libraries, The Lancet. Gastroenterology & hepatology, Hepatology, Nature Communications, and SSRN Electronic Journal.

John G. McHutchison has been recognized with awards including Fellowship of the Australian Academy of Health and Medical Science in 2018 and membership in the Association of American Physicians.

Best Publications

  • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

    Michael P. Manns;John G. McHutchison;Stuart C. Gordon;Vinod K. Rustgi

  • Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

    John G. Mchutchison;Stuart C. Gordon;Eugene R. Schiff;Mitchell L. Shiffman

  • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

    Dongliang Ge;Jacques Fellay;Alexander J. Thompson;Jason S. Simon

  • Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

    Ira M. Jacobson;John G. McHutchison;Geoffrey Dusheiko;Adrian M. Di Bisceglie

  • Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

    David L. Thomas;Chloe L Thio;Maureen P. Martin;Ying Qi

  • Sofosbuvir for previously untreated chronic hepatitis C infection

    Eric Lawitz;Alessandra Mangia;David Wyles;Maribel Rodriguez-Torres

  • Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

    Nezam Afdhal;Stefan Zeuzem;Paul Kwo;Mario Chojkier

  • Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

    Patrick Marcellin;Edward J Gane;Maria Buti;Nezam H Afdhal

  • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

    John G. McHutchison;Eric J. Lawitz;Mitchell L. Shiffman;Andrew J. Muir

  • Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

    Nezam Afdhal;K. Rajender Reddy;David R. Nelson;Eric Lawitz

  • Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

    Thierry Poynard;John McHutchison;Michael Manns;Christian Trepo

  • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

    Kris V. Kowdley;Stuart C. Gordon;K. Rajender Reddy;Lorenzo Rossaro

  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

    Ira M. Jacobson;Stuart C. Gordon;Kris V. Kowdley;Eric M. Yoshida

  • Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

    John G. McHutchison;Gregory T. Everson;Stuart C. Gordon;Ira M. Jacobson

  • Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

    Jordan J. Feld;Ira M. Jacobson;Christophe Hézode;Tarik Asselah

  • Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C

    John G. McHutchison;Michael Manns;Keyur Patel;Thierry Poynard

  • Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C

    Gary L. Davis;John B. Wong;John G. McHutchison;Michael P. Manns

  • Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

    Stefan Zeuzem;Geoffrey M. Dusheiko;Riina Salupere;Alessandra Mangia

  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  • Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C

    Thierry Poynard;Vlad Ratziu;Frédéric Charlotte;Zachary Goodman

Frequent Co-Authors

Andrew J. Muir
Andrew J. Muir Duke University
Mark S. Sulkowski
Mark S. Sulkowski Johns Hopkins University School of Medicine
Nezam H. Afdhal
Nezam H. Afdhal Beth Israel Deaconess Medical Center
Ira M. Jacobson
Ira M. Jacobson New York University
Eric Lawitz
Eric Lawitz The University of Texas at Austin
Alexander J. Thompson
Alexander J. Thompson Ascension Health
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Hongmei Mo
Hongmei Mo Gilead Sciences (United States)
Hans L. Tillmann
Hans L. Tillmann East Carolina University
Mitchell L. Shiffman
Mitchell L. Shiffman Bon Secours Health System

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online healthcare degrees can open new career pathways for those interested in medicine, but seeking flexibility. For future healthcare leaders, there are several cahme accredited online healthcare administration programs that deliver rigorous training in administration and policy, preparing graduates for management roles in hospitals and clinics.

If you’re already a registered nurse, enrolling in an rn to bsn online with no clinicals program can help you advance your credentials at your own pace, without the need for traditional clinical placements.

For nurses aiming to reach the highest levels of practice, there are options like the fastest dnp program, designed for rapid completion, as well as flexible dnp programs online that emphasize accessible pathways to advanced practice nursing.

These degree options can help you achieve your career goals while balancing personal and professional commitments, providing alternative routes to serving in the U.S. healthcare system.

Best Scientists Citing John G. McHutchison

Trending Scientists